Quark
Quark to Use Transplant Genomics Kidney Transplant Test in Clinical Study
Quark will use Transplant Genomics' test to monitor patient responses to its RNAi-based delayed graft function drug following kidney transplantation.
NEW YORK (GenomeWeb) – Quark Pharmaceuticals this week presented data from a Phase II trial of QPI-1002, an siRNA-based drug for the prevention of delayed graft function (DGF) in kidney transplant patients.
NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.
NEW YORK (GenomeWeb) – Quark Pharmaceuticals this week announced that it has completed a Phase II trial of its siRNA-based drug for the prevention of delayed graft function in kidney transplant patients.
NEW YORK (GenomeWeb) – Quark Pharmaceuticals announced this week that it has dosed the first patient in a Phase IIa study of QPI-1007, its siRNA-based treatment for glaucoma.
Dec 19, 2013
Jun 6, 2013
May 30, 2013
May 3, 2012
Apr 19, 2012
Feb 9, 2012
Jan 12, 2012
Nov 17, 2011
Sep 29, 2011
May 12, 2011
Mar 24, 2011
Feb 24, 2011
Feb 3, 2011